2012 update to the society of thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations

Annals of Thoracic Surgery

Volumn 94, Issue 5, 2012, Pages 1761-1781

  Ferraris, Victor A ^a   Saha, Sibu P ^a   Oestreich, Julie H ^b   Song, Howard K ^c   Rosengart, Todd ^d   Reece, T Brett ^e   Mazer, C David ^f   Bridges, Charles R ^g   Despotis, George J ^h   Jointer, Kanae ⁱ   Clough, Ellen R ⁱ  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g Sanger Clinic   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Society of Thoracic Surgeons   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; NONSTEROID ANTIINFLAMMATORY AGENT; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DYSPNEA; EXTRACORPOREAL OXYGENATION; HEART SURGERY; HEMOFILTRATION; HEMOPERFUSION; HUMAN; OFF PUMP CORONARY SURGERY; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVASCULARIZATION; RISK FACTOR; SIDE EFFECT; THROMBOCYTE AGGREGATION; URIC ACID BLOOD LEVEL;

CARDIAC SURGICAL PROCEDURES; DRUG MONITORING; EMERGENCY TREATMENT; HUMANS; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; RISK ASSESSMENT; RISK FACTORS;

EID: 84867793423     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2012.07.086     Document Type: Article

References (237)

1. V.A. Ferraris, S.P. Ferraris, D.J. Moliterno The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary) Ann Thorac Surg 79 2005 1454 1461
2. D.B. Jack One hundred years of aspirin Lancet 350 1997 437 439
3. J. Miner, A. Hoffhines The discovery of aspirin's antithrombotic effects Tex Heart Inst J 34 2007 179 186
4. G.J. Roth, N. Stanford, P.W. Majerus Acetylation of prostaglandin synthase by aspirin Proc Natl Acad Sci USA 72 1975 3073 3076
5. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
6. S.R. Mehta, J.P. Bassand, S. Chrolavicius Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
7. V.A. Ferraris, S.P. Ferraris, S.P. Saha Antiplatelet drugs: mechanisms and risks of bleeding following cardiac operations Int J Angiol 20 2011 1 18
8. P. Henry, A. Vermillet, B. Boval 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease Thromb Haemost 105 2011 336 344
9. M. Lordkipanidze Why an aspirin a day no longer keeps the doctor away Thromb Haemost 105 2011 209 210
10. J.M. Sweeny, D.A. Gorog, V. Fuster Antiplatelet drug "resistance. " Part 1: mechanisms and clinical measurements Nat Rev Cardiol 6 2009 273 282
11. V.L. Serebruany, A.I. Malinin, W. Ziai Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial Stroke 36 2005 2289 2292
12. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
13. G. Davi, C. Patrono Platelet activation and atherothrombosis N Engl J Med 357 2007 2482 2494
14. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
15. S.R. Steinhubl, P.B. Berger, J.T. Mann Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420
16. L. Wallentin, R.C. Becker, A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
17. S.D. Wiviott, E. Braunwald, C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
18. M.J. Quinn, D.J. Fitzgerald Ticlopidine and clopidogrel Circulation 100 1999 1667 1672
19. K. Hagihara, Y. Nishiya, A. Kurihara, M. Kazui, N.A. Farid, T. Ikeda Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine Drug Metab Pharmacokinet 23 2008 412 420
20. J.L. Mega, S.L. Close, S.D. Wiviott Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
21. J.T. Brandt, C.D. Payne, S.D. Wiviott A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 2007 66 e9-16
22. L. Wallentin, C. Varenhorst, S. James Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 2008 21 30
23. Prasugrel prescribing information http://www.effient.com 2011 Accessed January 1, 2012
24. M. Anselmino, K. Malmberg, J. Ohrvik, L. Ryden Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart Eur J Cardiovasc Prev Rehabil 15 2008 216 223
25. J.L. Anderson, C.D. Adams, E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) J Am Coll Cardiol 50 2007 e1 e157
26. J. Dunning, M. Versteegh, A. Fabbri Guideline on antiplatelet and anticoagulation management in cardiac surgery Eur J Cardiothorac Surg 34 2008 73 92
27. V.A. Ferraris, J.R. Brown, G.J. Despotis 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines Ann Thorac Surg 91 2011 944 982
28. Brilinta prescribing information http://www.brilintatouchpoints.com/?wt. mc-id=brldh10675&wt.srch=1&pkw=ticagrelor%20package%20insert&source= brldh10675&umedium=paid%20search&uadpub=google&ucreative= prescribing%20information&ucampaign=version1#isi.(9/20/2011) 2011 Accessed December 31, 2011
29. Ticagrelor prescribing information http://www1.astrazeneca-us.com/pi/ brilinta.pdf Accessed August 8, 2011
30. J.J. Vang, L. Nilsson, P. Berntsson Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation J Thromb Haemost 7 2009 1556 1565
31. P.A. Gurbel, K.P. Bliden, K. Butler Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
32. R.F. Storey Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors Thromb Haemost 105 Suppl 1 2011 75 81
33. W.S. Akers, J.J. Oh, J.H. Oestreich, S. Ferraris, M. Wethington, S.R. Steinhubl Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist J Clin Pharmacol 50 2010 27 35
34. D.L. Bhatt, A.M. Lincoff, C.M. Gibson Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
35. R.A. Harrington, G.W. Stone, S. McNulty Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
36. Angiolillo A. Cangrelor provides effective maintenance of platelet inhibition without major bleeding for patients who require bypass surgery. Paper presented at: the 23rd Annual Transcatheter Cardiovascular Therapeutics Scientific Symposium; November 9, 2011; San Francisco, California.
37. J.H. Oestreich Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events Curr Opin Invest Drugs 11 2010 340 348
38. M. Brambilla, A. Parolari, M. Camera Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery Thromb Haemost 103 2010 516 524
39. C. Patrono, B. Coller, G.A. FitzGerald, J. Hirsh, G. Roth Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 Suppl 2004 234 264
40. A.M. Lincoff, R.M. Califf, E.J. Topol Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease J Am Coll Cardiol 35 2000 1103 1115
41. J.C. Reverter, S. Beguin, H. Kessels, R. Kumar, H.C. Hemker, B.S. Coller Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest 98 1996 863 874
42. Y. Ikeda, T. Sudo, Y. Kumura Cilostazol A.D. Michelson, Platelets 2nd ed. 2007 Elsevier Oxford, UK 1181 1191
43. R. Hall, C.D. Mazer Antiplatelet drugs: a review of their pharmacology and management in the perioperative period Anesth Analg 112 2011 292 318
44. J.W. Suh, S.P. Lee, K.W. Park Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (Influence of Cilostazol-Based Triple Antiplatelet Therapy on Ischemic Complication After Drug-Eluting Stent Implantation) trial J Am Coll Cardiol 57 2011 280 289
45. O. Yousuf, D.L. Bhatt The evolution of antiplatelet therapy in cardiovascular disease Nat Rev Cardiol 8 2011 547 559
46. W.G. Eisert Dipyridamole A.D. Michelson, Platelets 2nd ed. 2007 Elsevier Oxford, UK 1165 1179
47. V.A. Ferraris, S.P. Ferraris Limiting excessive postoperative blood transfusion after cardiac procedures A review Tex Heart Inst J 22 1995 216 230
48. S.R. Mehta, S. Yusuf, R.J. Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
49. S.S. Nijjer, G. Watson, T. Athanasiou, I.S. Malik Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies Eur Heart J 32 2011 2970 2988
50. M. Jacob, N. Smedira, E. Blackstone, S. Williams, L. Cho Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery Circulation 123 2011 577 583
51. R.A. White, D.C. Miller, F.J. Criado Report on the results of thoracic endovascular aortic repair for acute, complicated, type B aortic dissection at 30 days and 1 year from a multidisciplinary subcommittee of the Society for Vascular Surgery Outcomes Committee J Vasc Surg 53 2011 1082 1090
52. T. Sachs, F. Pomposelli, R. Hagberg Open and endovascular repair of type B aortic dissection in the Nationwide Inpatient Sample J Vasc Surg 52 2010 860 866
53. D. Cheng, J. Martin, H. Shennib Endovascular aortic repair versus open surgical repair for descending thoracic aortic disease a systematic review and meta-analysis of comparative studies J Am Coll Cardiol 55 2010 986 1001
54. B.J. Orandi, J.B. Dimick, G.M. Deeb, H.J. Patel, G.R. Upchurch A population-based analysis of endovascular versus open thoracic aortic aneurysm repair J Vasc Surg 49 2009 1112 1116
55. S.S. Nijjer, G. Watson, T. Athanasiou, I.S. Malik Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies Eur Heart J 32 2011 2970 2988
56. T.L. Frankel, S.C. Stamou, R.C. Lowery Risk factors for hemorrhage-related reexploration and blood transfusion after conventional versus coronary revascularization without cardiopulmonary bypass Eur J Cardiothorac Surg 27 2005 494 500
57. J.Y. Leong, R.A. Baker, P.J. Shah, V.K. Cherian, J.L. Knight Clopidogrel and bleeding after coronary artery bypass graft surgery Ann Thorac Surg 80 2005 928 933
58. D.J. Perry, D.A. Fitzmaurice, S. Kitchen, I.J. Mackie, S. Mallett Point-of-care testing in haemostasis Br J Haematol 150 2010 501 514
59. U. Shah, A.D. Ma Tests of platelet function Curr Opin Hematol 14 2007 432 437
60. S. Agarwal, M. Coakley, K. Reddy, A. Riddell, S. Mallett Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry Anesthesiology 105 2006 676 683
61. M.S. Avidan, E.L. Alcock, J. Da Fonseca Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery Br J Anaesth 92 2004 178 186
62. U. Cammerer, W. Dietrich, T. Rampf, S.L. Braun, J.A. Richter The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery Anesth Analg 96 2003 51 57
63. M.H. Ereth, G.A. Nuttall, J.T. Klindworth Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass? Anesth Analg 85 1997 259 264
64. N. Faraday, E. Guallar, V.A. Sera Utility of whole blood hemostatometry using the clot signature analyzer for assessment of hemostasis in cardiac surgery Anesthesiology 96 2002 1115 1122
65. P.E. Greilich, B.M. Alving, D. Longnecker Near-site monitoring of the antiplatelet drug abciximab using the Hemodyne analyzer and modified thrombelastograph J Cardiothorac Vasc Anesth 13 1999 58 64
66. J. Ostrowsky, J. Foes, M. Warchol, G. Tsarovsky, J. Blay PlateletWorks platelet function test compared with the thromboelastograph for prediction of postoperative outcomes J Extra Corpor Technol 36 2004 149 152
67. H. Pleym, A. Wahba, L. Bjella, R. Stenseth Sonoclot analysis in elderly compared with younger patients undergoing coronary surgery Acta Anaesthesiol Scand 52 2008 28 35
68. N. Savion, D. Varon Impact - the cone and plate(let) analyzer: testing platelet function and anti-platelet drug response Pathophysiol Haemost Thromb 35 2006 83 88
69. D. Sibbing, S. Braun, S. Jawansky Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment Thromb Haemost 99 2008 121 126
70. D. Sibbing, S. Braun, T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
71. D. Sibbing, T. Morath, S. Braun Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting Thromb Haemost 103 2010 151 159
72. N. von Beckerath, A. Kastrati, A. Wieczorek A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur Heart J 28 2007 1814 1819
73. M. Ranucci, E. Baryshnikova, G. Soro, A. Ballotta, D. De Benedetti, D. Conti Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines Ann Thorac Surg 91 2011 123 129
74. G.J. Despotis, V. Levine, K.S. Filos Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients Anesthesiology 85 1996 1311 1323
75. J. Koscielny, S. Ziemer, H. Radtke [Preoperative identification of patients with impaired (primary) haemostasis A practical concept.] Hamostaseologie 27 2007 177 184
76. G. Patti, V. Pasceri, V. Vizzi, E. Ricottini, G. Di Sciascio Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study) Am J Cardiol 107 2011 995 1000
77. L.J. Enriquez, L. Shore-Lesserson Point-of-care coagulation testing and transfusion algorithms Br J Anaesth 103 Suppl 1 2009 i14 i22
78. E. Girdauskas, J. Kempfert, T. Kuntze Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial J Thorac Cardiovasc Surg 140 2010 1117-24.e2
79. C.F. Weber, W. Dietrich, M. Spannagl, C. Hofstetter, C. Jambor A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole-blood aggregometry in patients after cardiac surgery Anesth Analg 110 2010 702 707
80. A.J. Westbrook, J. Olsen, M. Bailey, J. Bates, M. Scully, R.F. Salamonsen Protocol based on thromboelastograph (TEG) out-performs physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery: a pilot study Heart Lung Circ 18 2009 277 288
81. R. Pakala, R. Waksman Currently available methods for platelet function analysis: advantages and disadvantages Cardiovasc Revasc Med 12 2011 312 322
82. H. Seidel, M.M. Rahman, R.E. Scharf [Monitoring of antiplatelet therapy. Current limitations, challenges, and perspectives.] Hamostaseologie 31 2011 41 51
83. R. Gertler, G. Wiesner, P. Tassani-Prell, S.L. Braun, K. Martin Are the point-of-care diagnostics Multiplate and ROTEM valid in the setting of high concentrations of heparin and its reversal with protamine? J Cardiothorac Vasc Anesth 25 2011 981 986
84. S.M. Picker In-vitro assessment of platelet function Transfus Apheres Sci 44 2011 305 319
85. P. Harrison, H. Segal, K. Blasbery, C. Furtado, L. Silver, P.M. Rothwell Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry Stroke 36 2005 1001 1005
86. E.H. Elsenberg, J.W. van Werkum, R.M. van de Wal The influence of clinical characteristics, laboratory and inflammatory markers on "high on-treatment platelet reactivity" as measured with different platelet function tests Thromb Haemost 102 2009 719 727
87. M.H. Ereth, G.A. Nuttall, D.G. Ericson Platelet glass bead retention predicts bleeding after cardiac surgery J Cardiothorac Vasc Anesth 15 2001 49 54
88. J. Mortensen, T.S. Poulsen, E.L. Grove Monitoring aspirin therapy with the Platelet Function Analyzer-100 Scand J Clin Lab Invest 68 2008 786 792
89. Z. Motovska, Z. Sujanova, S. Wimmerova, J. Ardo, M. Skrakova, P. Widimsky Comparison of cationic propyl gallate and adenosine diphosphate for the measurement of aspirin effectivity with optical aggregometry Transl Res 150 2007 246 252
90. G.A. Nuttall, W.C. Oliver, D.N. Fass A prospective, randomized platelet-function study of heparinized oxygenators and cardiotomy suction J Cardiothorac Vasc Anesth 20 2006 554 561
91. J.J. Smit, W. van Oeveren, J.P. Ottervanger Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST-segment elevation myocardial infarction Eur J Clin Invest 39 2009 103 109
92. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study J Invasive Cardiol 16 2004 325 329
93. E. Arosio, P. Minuz, M. Prior Vascular adhesion molecule-1 and markers of platelet function before and after a treatment with iloprost or a supervised physical exercise program in patients with peripheral arterial disease Life Sci 69 2001 421 433
94. A.M. Blaicher, H.T. Landsteiner, O. Al-Falaki Acetylsalicylic acid, diclofenac, and lornoxicam, but not rofecoxib, affect platelet CD 62 expression Anesth Analg 98 2004 1082 1085
95. A. Franz, P. Braunlich, T. Gamsjager, M. Felfernig, B. Gustorff, S.A. Kozek-Langenecker The effects of hydroxyethyl starches of varying molecular weights on platelet function Anesth Analg 92 2001 1402 1407
96. J. Geiger, L. Teichmann, R. Grossmann Monitoring of clopidogrel action: comparison of methods Clin Chem 51 2005 957 965
97. M.J. Quinn, R.T. Murphy, M. Dooley, J.B. Foley, D.J. Fitzgerald Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion J Pharmacol Exp Ther 297 2001 496 500
98. V.L. Serebruany, A.I. Malinin, C.M. O'Connor, P.A. Gurbel Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I platelet substudy) Am Heart J 146 2003 91 98
99. V.L. Serebruany, A.I. Malinin, D.C. Sane Magnitude and time course of platelet inhibition with Aggrenox and aspirin in patients after ischemic stroke: the Aggrenox Versus Aspirin Therapy Evaluation (AGATE) trial Eur J Pharmacol 499 2004 315 324
100. J.M. Ten Berg, W.B. Gerritsen, F.J. Haas, J.C. Kelder, F.W. Verheugt, H.W. Thijs Plokker Pretreatment with oral anticoagulants decreases platelet activation in patients before and after percutaneous coronary intervention Thromb Haemost 88 2002 924 930
101. V.A. Ferraris, S.P. Ferraris, A. Singh The platelet thrombin receptor and postoperative bleeding Ann Thorac Surg 65 1998 352 358
102. J.E. Freedman, C. Parker, L. Li Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release Circulation 103 2001 2792 2798
103. S. Guthikonda, E.I. Lev, R. Patel Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin J Thromb Haemost 5 2007 490 496
104. P.T. Leese, S. Talwalker, J.D. Kent, D.P. Recker Valdecoxib does not impair platelet function Am J Emerg Med 20 2002 275 281
105. E. Munsterhjelm, T.T. Niemi, M.T. Syrjala, O. Ylikorkala, P.H. Rosenberg Propacetamol augments inhibition of platelet function by diclofenac in volunteers Br J Anaesth 91 2003 357 362
106. M. Yemisci, H. Ay, C. Kocaefe Statin potentiates human platelet eNOS activity without enhancing eNOS mRNA and protein levels Cerebrovasc Dis 26 2008 190 198
107. J.C. Sun, R. Whitlock, J. Cheng The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies Eur Heart J 29 2008 1057 1071
108. A.A. Alghamdi, F. Moussa, S.E. Fremes Does the use of preoperative aspirin increase the risk of bleeding in patients undergoing coronary artery bypass grafting surgery? Systematic review and meta-analysis J Card Surg 22 2007 247 256
109. M.H. Ghaffarinejad, A.F. Fazelifar, S.M. Shirvani The effect of preoperative aspirin use on postoperative bleeding and perioperative myocardial infarction in patients undergoing coronary artery bypass surgery Cardiol J 14 2007 453 457
110. L.C. Wallentin Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization Research Group on Instability in Coronary Artery Disease in Southeast Sweden J Am Coll Cardiol 18 1991 1587 1593
111. K.A. Fox, S.R. Mehta, R. Peters Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable Angina to Prevent Recurrent ischemic Events (CURE) trial Circulation 110 2004 1202 1208
112. L. Cao, N. Young, H. Liu Preoperative aspirin use and outcomes in cardiac surgery patients Ann Surg 255 2011 399 404
113. A.S. Jassar, P.A. Ford, H.L. Haber Cardiac surgery in Jehovah's Witness patients: ten-year experience Ann Thorac Surg 93 2012 19 25
114. B.R. Dandolu, J. Parmet, A. Isidro Reoperative cardiac surgery in Jehovah's Witness patients with patent internal thoracic artery grafts: how far can we push the envelope? Heart Surg Forum 11 2008 E32 E33
115. V. Casati, A. D'Angelo, L. Barbato Perioperative management of four anaemic female Jehovah's Witnesses undergoing urgent complex cardiac surgery Br J Anaesth 99 2007 349 352
116. S. Jovanovic, S.D. Hansbro, C.M. Munsch, M.H. Cross Redo cardiac surgery in a Jehovah's Witness, the importance of a multidisciplinary approach to blood conservation Perfusion 15 2000 251 255
117. T.K. Rosengart, R.E. Helm, W.J. DeBois, N. Garcia, K.H. Krieger, O.W. Isom Open heart operations without transfusion using a multimodality blood conservation strategy in 50 Jehovah's Witness patients: implications for a "bloodless" surgical technique J Am Coll Surg 184 1997 618 629
118. D.A. Ott, D.A. Cooley Cardiovascular surgery in Jehovah's Witnesses Report of 542 operations without blood transfusion JAMA 238 1977 1256 1258
119. C.E. Firanescu, E.J. Martens, J.P. Schonberger, M.A. Soliman Hamad, A.H. van Straten Postoperative blood loss in patients undergoing coronary artery bypass surgery after preoperative treatment with clopidogrel A prospective randomised controlled study Eur J Cardiothorac Surg 36 2009 856 862
120. C. Held, N. Asenblad, J.P. Bassand Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial J Am Coll Cardiol 57 2011 672 684
121. J.S. Li, J.W. Newburger Antiplatelet therapy in pediatric cardiovascular patients Pediatr Cardiol 31 2010 454 461
122. V. Casati, A. D'Angelo, L. Barbato Perioperative management of a heterozygous carrier of Glanzmann's thrombasthenia submitted to coronary artery bypass grafting with cardiopulmonary bypass Anesth Analg 103 2006 309 311
123. I.J. Welsby, D.M. Monroe, J.H. Lawson, M. Hoffmann Recombinant activated factor VII and the anaesthetist Anaesthesia 60 2005 1203 1212
124. M. Ono, H. Goerler, T. Breymann Aneurysm of the aortic root in the setting of Wiskott-Aldrich syndrome Cardiol Young 19 2009 212 215
125. P. Narayan, H. Alwair, A.J. Bryan Surgical resection of sequential thoracic aortic aneurysms in Wiskott-Aldrich syndrome Interact Cardiovasc Thorac Surg 3 2004 346 348
126. J.A. Van Son, A.S. O'Marcaigh, W.D. Edwards, P.R. Julsrud, G.K. Danielson Successful resection of thoracic aortic aneurysms in Wiskott-Aldrich syndrome Ann Thorac Surg 60 1995 685 687
127. R.D. McBane, J.M. Panneton, W.W. Bate Aortic thrombosis as a complication of paroxysmal nocturnal hemoglobinuria Circulation 104 2001 E1 E2
128. K. Knobloch, A. Lichtenberg, R.G. Leyh, J. Schubert Aortic valve replacement and coronary revascularization in paroxysmal nocturnal hemoglobinuria Interact Cardiovasc Thorac Surg 2 2003 647 649
129. T. Mattina, C.S. Perrotta, P. Grossfeld Jacobsen syndrome Orphanet J Rare Dis 4 2009 9
130. N. Naqvi, S.J. Davidson, D. Wong Predicting 22q11.2 deletion syndrome: a novel method using the routine full blood count Int J Cardiol 150 2011 50 53
131. M.T. Arslan, R. Ozyurek, K. Kavakli Frequency of acquired von Willebrand's disease in children with congenital heart disease Acta Cardiol 62 2007 403 408
132. K. Shaikhrezai, U. Bashir, S. Millar, J. Anderson, E.T. Brackenbury Redo-redo aortic root replacement with a mechanical valved conduit in a patient with von Willebrand's disease: case report J Cardiothorac Surg 5 2010 59
133. M. Cattaneo The use of desmopressin in open-heart surgery Haemophilia 14 Suppl 1 2008 40 47
134. M.D. Reller Congenital heart disease: current indications for antithrombotic therapy in pediatric patients Curr Cardiol Rep 3 2001 90 95
135. J.M. Cholette, J.S. Rubenstein, G.M. Alfieris Elevated risk of thrombosis in neonates undergoing initial palliative cardiac surgery Ann Thorac Surg 84 2007 1320 1325
136. S.J. Israels, A.D. Michelson Antiplatelet therapy in children Thromb Res 118 2006 75 83
137. D.C. Kress, S. Aronson, M.L. McDonald Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes Ann Thorac Surg 83 2007 1737 1743
138. J.R. Bartholomew The incidence and clinical features of heparin-induced thrombocytopenia Semin Hematol 42 Suppl 3 2005 3 8
139. B.D. Spiess Update on heparin-induced thrombocytopenia and cardiovascular interventions Semin Hematol 42 Suppl 3 2005 22 27
140. S. Christiansen, K. Redmann, C. Schmid, H.H. Scheld Treatment strategy and perioperative risk in patients with idiopathic thrombocytopenic purpura undergoing cardiac surgery Thorac Cardiovasc Surg 49 2001 316 317
141. J.H. Levy, A.M. Winkler Heparin-induced thrombocytopenia and cardiac surgery Curr Opin Anaesthesiol 23 2010 74 79
142. M. Marchetti, A. Falanga Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders Pathophysiol Haemost Thromb 36 2008 148 159
143. R. Landolfi, M.A. Nicolazzi, A. Porfidia, L. Di Gennaro Polycythemia vera Intern Emerg Med 5 2010 375 384
144. P.A. Casthely, V. Defilippi, L. Cornwell Preoperative heparin therapy causes immune-mediated hypotension upon heparin administration for cardiac surgery J Cardiothorac Vasc Anesth 24 2010 69 72
145. S. Christiansen, J. Rotker, N. Roeder Are patients with Werlhof's disease at increased risk for bleeding complications when undergoing cardiac surgery? Eur J Cardiothorac Surg 18 2000 353 356
146. K.M. Richards, V.A. Ferraris Mitral valve replacement in a patient with idiopathic thrombocytopenic purpura: preoperative treatment with danazol J Cardiovasc Surg (Torino) 32 1991 840 842
147. A. Oscarsson, A. Gupta, M. Fredrikson To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial Br J Anaesth 104 2010 305 312
148. W. Korte, M. Cattaneo, P.G. Chassot Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the Working Group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the Working Group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (OGARI), and the Working Group on Thrombosis of the European Society for Cardiology (ESC) Thromb Haemost 105 2011 743 749
149. G.G. Biondi-Zoccai, M. Lotrionte, P. Agostoni A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease Eur Heart J 27 2006 2667 2674
150. J.C. Merritt, D.L. Bhatt The efficacy and safety of perioperative antiplatelet therapy J Thromb Thrombol 17 2004 21 27
151. J. Mantz, C.M. Samama, F. Tubach Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial Br J Anaesth 107 2011 899 910
152. A. Algra, J. van Gijn Is clopidogrel superior to aspirin in secondary prevention of vascular disease? Curr Control Trial Cardiovasc Med 1 2000 143 145
153. L.A. Fleisher, J.A. Beckman, K.A. Brown ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Circulation 116 2007 1971 1996
154. P. Albaladejo, E. Marret, C.M. Samama Non-cardiac surgery in patients with coronary stents: the RECO study Heart 97 2011 1566 1572
155. J. Winning, J. Neumann, M. Kohl Antiplatelet drugs and outcome in mixed admissions to an intensive care unit Crit Care Med 38 2010 32 37
156. J.W. Eikelboom, J. Hirsh Bleeding and management of bleeding Eur Heart J 8 Suppl G 2006 38 45
157. W. Burger, J.M. Chemnitius, G.D. Kneissl, G. Rucker Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation Review and meta-analysis J Intern Med 257 2005 399 414
158. T.W. Chapman, D.M. Bowley, A.W. Lambert, A.J. Walker, S.A. Ashley, D.C. Wilkins Haemorrhage associated with combined clopidogrel and aspirin therapy Eur J Vasc Endovasc Surg 22 2001 478 479
159. M. Moore, M. Power Perioperative hemorrhage and combined clopidogrel and aspirin therapy Anesthesiology 101 2004 792 794
160. A. Ernst, R. Eberhardt, M. Wahidi, H.D. Becker, F.J. Herth Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans Chest 129 2006 734 737
161. S.H. Wilson, P. Fasseas, J.L. Orford Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting J Am Coll Cardiol 42 2003 234 240
162. O. Schouten, R.T. van Domburg, J.J. Bax Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events J Am Coll Cardiol 49 2007 122 124
163. J.A. Rabbitts, G.A. Nuttall, M.J. Brown Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents Anesthesiology 109 2008 596 604
164. V.A. Ferraris, E. Swanson Aspirin usage and perioperative blood loss in patients undergoing unexpected operations Surg Gynecol Obstet 156 1983 439 442
165. I. Iakovou, T. Schmidt, E. Bonizzoni Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130
166. Z. Motovska Management of antiplatelet therapy inpatients at risk for coronary stent thrombosis undergoing non-cardiac surgery Drugs 71 2011 1797 1806
167. K.K. Chia, J.J. Park, J. Postle, A. Cottrill, M.R. Ward Frequency of late drug-eluting stent thrombosis with non-cardiac surgery Am J Cardiol 106 2010 1 3
168. C.L. Grines, R.O. Bonow, D.E. Casey Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians J Am Dent Assoc 138 2007 652 655
169. P. Albaladejo, E. Marret, V. Piriou, C.M. Samama French Society of Anesthesiology and Intensive Care Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French task force Br J Anaesth 97 2006 580 582
170. S.E. Fremes, C. Levinton, C.D. Naylor, E. Chen, G.T. Christakis, B.S. Goldman Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis Eur J Cardiothorac Surg 7 1993 169 180
171. J. Dunning, M. Versteegh, A. Fabbri Guideline on antiplatelet and anticoagulation management in cardiac surgery Eur J Cardiothorac Surg 34 2008 73 92
172. P.D. Stein, H.J. Schunemann, J.E. Dalen, D. Gutterman Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 Suppl 2004 600 608
173. N. Sawhney, J.W. Moses, M.B. Leon Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents Circulation 110 2004 374 379
174. L.D. Hillis, P.K. Smith, J.L. Anderson 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 124 2011 2610 2642
175. G.N. Levine, E.R. Bates, J.C. Blankenship 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions Circulation 124 2011 2574 2609
176. R. Sorensen, S.Z. Abildstrom, P.R. Hansen Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction J Am Coll Cardiol 57 2011 1202 1209
177. G. Gao, Z. Zheng, Y. Pi, B. Lu, J. Lu, S. Hu Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial J Am Coll Cardiol 56 2010 1639 1643
178. J. Borgermann, A. Kanashnik, M. Sossdorf, J. Gummert, W. Losche Individual variability of response and non-response to acetyl salicylic acid after cardiac surgery Platelets 21 2010 610 615
179. F. Bednar, P. Osmancik, J. Hlavicka, V. Jedlickova, Z. Paluch, T. Vanek Aspirin is insufficient in inhibition of platelet aggregation and thromboxane formation early after coronary artery bypass surgery J Thromb Thrombol 27 2009 394 399
180. F. Bednar, P. Osmancik, T. Vanek Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: results from the prospective randomized trial PRAGUE 11-Coronary Artery Bypass and Reactivity of Thrombocytes (CABARET) J Thorac Cardiovasc Surg 136 2008 1054 1060
181. T.J. Gluckman, R.C. McLean, S.P. Schulman Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery J Am Coll Cardiol 57 2011 1069 1077
182. J.D. Snoep, M.M. Hovens, J.C. Eikenboom, J.G. van der Bom, M.V. Huisman Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis Arch Intern Med 167 2007 1593 1599
183. G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca, G. Di Sciascio High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study J Am Coll Cardiol 57 2011 771 778
184. D. Alexopoulos, G. Dimitropoulos, P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping J Am Coll Cardiol Intv 4 2011 403 410
185. G. Parodi, R. Marcucci, R. Valenti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
186. D. Sibbing, R.A. Byrne, I. Bernlochner, A. Kastrati High platelet reactivity and clinical outcome - fact and fiction Thromb Haemost 106 2011 191 202
187. H. Fernando, A.M. Dart, K. Peter, J.A. Shaw Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy Thromb Haemost 105 2011 933 944
188. G. Pare, S.R. Mehta, S. Yusuf Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 2010 1704 1714
189. J.L. Mega, W. Hochholzer, A.L. Frelinger Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease JAMA 306 2011 2221 2228
190. R.H. Mehta, A.Y. Chen, C.V. Pollack Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes Am J Cardiol 98 2006 624 627
191. J.H. Oestreich, S.R. Steinhubl, S.P. Ferraris, W.S. Akers High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the double-standard dose in an assay-dependent manner Thromb Haemost 105 2011 927 930
192. F. Biancari, K.E. Airaksinen, G.Y. Lip Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies J Thorac Cardiovasc Surg 2011 June 24 [E-pub ahead of print]
193. S. Savonitto, M. D'Urbano, M. Caracciolo Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of "bridging" antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel Br J Anaesth 104 2010 285 291
194. J.S. Berger, C.B. Frye, Q. Harshaw, F.H. Edwards, S.R. Steinhubl, R.C. Becker Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis J Am Coll Cardiol 52 2008 1693 1701
195. M.W. Chu, S.R. Wilson, R.J. Novick, L.W. Stitt, M.A. Quantz Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 78 2004 1536 1541
196. L.D. Hillis, P.K. Smith, J.L. Anderson 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 58 2011 2584 2614
197. L. Bonello, N. Bonello-Palot, S. Armero Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients Thromb Res 125 2010 e167 e170
198. F. Sofi, R. Marcucci, A.M. Gori, B. Giusti, R. Abbate, G.F. Gensini Clopidogrel non-responsiveness and risk of cardiovascular morbidity An updated meta-analysis Thromb Haemost 103 2010 841 848
199. P. Gladding, M. Webster, J. Ormiston, S. Olsen, H. White Antiplatelet drug nonresponsiveness Am Heart J 155 2008 591 599
200. Y.L. Kwak, J.C. Kim, Y.S. Choi, K.J. Yoo, Y. Song, J.K. Shim Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery J Am Coll Cardiol 56 2010 1994 2002
201. L. Chen, A.W. Bracey, R. Radovancevic Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting J Thorac Cardiovasc Surg 128 2004 425 431
202. C.R. Herman, K.J. Buth, B.A. Kent, G.M. Hirsch Clopidogrel increases blood transfusion and hemorrhagic complications in patients undergoing cardiac surgery Ann Thorac Surg 89 2010 397 402
203. H. Gasparovic, M. Petricevic, B. Biocina Reduction of thienopyridine-associated bleeding using multiple electrode whole-blood aggregometry Ann Thorac Surg 92 2011 778 779 author reply 779
204. G. Montalescot, S.D. Wiviott, E. Braunwald Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
205. M. De Carlo, D.A. Wood, J.G. Webb Adjunctive use of the Rinspiration system for fluidic thrombectomy during primary angioplasty: the Rinspiration international registry Catheter Cardiovasc Interv 72 2008 196 203
206. R. Ferrandis, J.V. Llau, A. Mugarra Perioperative management of antiplatelet-drugs in cardiac surgery Curr Cardiol Rev 5 2009 125 132
207. J. Thachil, A. Gatt, V. Martlew Management of surgical patients receiving anticoagulation and antiplatelet agents Br J Surg 95 2008 1437 1448
208. H.J. Priebe Triggers of perioperative myocardial ischaemia and infarction Br J Anaesth 93 2004 9 20
209. E. Mahla, H. Metzler, U.S. Tantry, P.A. Gurbel Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery Ann Thorac Surg 90 2010 1040 1051
210. N. Sambu, T. Warner, N. Curzen Clopidogrel withdrawal: is there a "rebound" phenomenon? Thromb Haemost 105 2011 211 220
211. J.W. Suh, R. Mehran, B.E. Claessen Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial J Am Coll Cardiol 58 2011 1750 1756
212. G. Ndrepepa, P.B. Berger, J. Mehilli Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point J Am Coll Cardiol 51 2008 690 697
213. R. Sarode How do I transfuse platelets (PLTs) to reverse anti-PLT drug effect? Transfusion 2011 Aug 19 [E-pub ahead of print]
214. C.F. Weber, K. Gorlinger, C. Byhahn Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy Eur J Anaesthesiol 28 2011 57 62
215. A. Sedrakyan, T. Treasure, J.A. Elefteriades Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials J Thorac Cardiovasc Surg 128 2004 442 448
216. R. Altman, A. Scazziota, M. Delh, C. Gonzalez Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation J Thromb Haemost 4 2006 2022 2027
217. S.A. Mayer, N.C. Brun, K. Begtrup Recombinant activated factor VII for acute intracerebral hemorrhage N Engl J Med 352 2005 777 785
218. M. Levi, J.H. Levy, H.F. Andersen, D. Truloff Safety of recombinant activated factor VII in randomized clinical trials N Engl J Med 363 2010 1791 1800
219. K.A. O'Connell, J.J. Wood, R.P. Wise, J.N. Lozier, M.M. Braun Thromboembolic adverse events after use of recombinant human coagulation factor VIIa JAMA 295 2006 293 298
220. R.D. Piers, E. Azoulay, B. Ricou Perceptions of appropriateness of care among European and Israeli intensive care unit nurses and physicians JAMA 306 2011 2694 2703
221. L.T. Goodnough, A. Shander Blood management Arch Pathol Lab Med 131 2007 695 701
222. T.G. Buchman, V.L. Patel, J. Dushoff McDonnell Norms Group Enhancing the use of clinical guidelines: a social norms perspective J Am Coll Surg 202 2006 826 836
223. F.A. Wolf, L.W. Way, L. Stewart The efficacy of medical team training: improved team performance and decreased operating room delays A detailed analysis of 4,863 cases Ann Surg 252 2010 477 485
224. J. Brevig, J. McDonald, E.S. Zelinka, T. Gallagher, R. Jin, G.L. Grunkemeier Blood transfusion reduction in cardiac surgery: multidisciplinary approach at a community hospital Ann Thorac Surg 87 2009 532 539
225. S. Verma, M. Eisses, M. Richards Blood conservation strategies in pediatric anesthesia Anesthesiol Clin 27 2009 337 351
226. J.J. Francis, C. Stockton, M.P. Eccles Evidence-based selection of theories for designing behaviour change interventions: using methods based on theoretical construct domains to understand clinicians' blood transfusion behaviour Br J Health Psychol 14 2009 625 646
227. S.M. Reddy, S. Talwar, D. Velayoudam Multi-modality blood conservation strategy in open-heart surgery: an audit Interact Cardiovasc Thorac Surg 9 2009 480 482
228. S. Hunziker, A.C. Johansson, F. Tschan Teamwork and leadership in cardiopulmonary resuscitation J Am Coll Cardiol 57 2011 2381 2388
229. J.M. Schraagen, T. Schouten, M. Smit A prospective study of paediatric cardiac surgical microsystems: assessing the relationships between non-routine events, teamwork and patient outcomes BMJ Qual Safety 20 2011 599 603
230. M.J. Burtscher, T. Manser, M. Kolbe Adaptation in anaesthesia team coordination in response to a simulated critical event and its relationship to clinical performance Br J Anaesth 106 2011 801 806
231. J.H. Levy, R.P. Dutton, J.C. Hemphill Multidisciplinary approach to the challenge of hemostasis Anesth Analg 110 2010 354 364
232. E. Al-Shawaf, A. Ayed, I. Vislocky, B. Radomir, N. Dehrab, R. Tarazi Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery J Cardiothorac Vasc Anesth 20 2006 353 357
233. Integrilin prescribing information http://www.integrilin.com 2011 Accessed January 11, 2012
234. Aggrastat prescribing information http://www.aggrastat.com 2008 Accessed January 11, 2012
235. Pletal prescribing information http://www.otsuka-us.com 2007 Accessed January 11, 2012
236. Aggrenox prescribing information http://www.aggrenox.com 2011 Accessed January 11, 2012
237. S.A. Hassantash, G.R. Omrani, N. Givtaj, M. Afrakhteh Pharmacological prevention of the deleterious effects of cardiopulmonary bypass Asian Cardiovasc Thorac Ann 15 2007 218 224